Abstracts tagged "AS"

Abstract Number: 819 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a 52-Week Phase 3 Randomized Placebo-Controlled Trial with Intravenous Loading and Subcutaneous Maintenance Dosing
Dominique L. Baeten¹, Juergen Braun², Xenofon Baraliakos³, Joachim Sieper⁴, Maxime Dougados⁵, Paul Emery⁶, Atul A. Deodhar⁷, Brian Porter⁸, Ruvie Martin⁸, Shephard Mpofu⁹ and Hanno Richards¹⁰, ¹Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Charité University Medicine Berlin, Berlin, Germany, ⁵Université Paris René Descartes and Hôpital Cochin, Paris, France, ⁶University of Leeds, Leeds, United Kingdom, ⁷Oregon Health and Sciences University, Portland, OR, ⁸Novartis Pharma AG, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland
Background/Purpose A phase 2, proof-of-concept study indicated that secukinumab, an anti–IL-17A monoclonal antibody, suppressed signs and symptoms of active ankylosing spondylitis (AS) by Week (Wk)…
Abstract Number: 2478 • 2013 ACR/ARHP Annual Meeting
Clinical Characteristics Of Patients With Early Spondyloarthritis. Results From a Specialized Consultation In a Clinical Hospital
Juan Jose Aznar Sánchez, Eugenio Chamizo Carmona, Adela Gallego Flores, Raul Veroz Gonzalez and Tamara Libertad Rodriguez Araya, Rheumatology, Hospital de Mérida, Mérida, Spain
Background/Purpose: The classification criteria for spondyloarthritis (SpA) intend to identify patients with this disease from the initial stages. The nonspecific characteristics, symptoms, signs, and additional…
Abstract Number: 531 • 2013 ACR/ARHP Annual Meeting
Influenza Infection Of MHC-I Transgenic Mice Reveals That Erap Is Necessary and Sufficient For Generation Of The B27-Specific Immunodominant Epitope
Ali Akram¹ and Robert Inman², ¹Institute of Medical Science and Department of Immunology, University of Toronto and University Health Network (UHN), Toronto, ON, Canada, ²Immunlogy and Institute of Medical Science, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Although HLA-B27 and ERAP are known to confer susceptibility to spondyloarthritis (SpA), the role of these elements in modulating host response to infection is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].